NMTC
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
NeuroOne Medical Technologies Corporation (NMTC) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (F). The rating has held at C for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (3.0) | C+ (2.6) | C+ (2.6) | F (0.7) | C+ (2.6) | C (2.3) |
| 2026-11-06 | B- (3.0) | C+ (2.6) | C+ (2.6) | D- (0.9) | C+ (2.7) | C (2.4) |
| 2026-10-30 | B- (3.0) | C+ (2.6) | C+ (2.7) | D- (0.9) | C+ (2.7) | C (2.4) |
| 2026-10-23 | B- (3.0) | C+ (2.6) | C+ (2.7) | D- (0.8) | C+ (2.6) | C (2.3) |
| 2026-10-16 | B- (3.0) | C+ (2.6) | C+ (2.7) | D- (0.7) | C+ (2.6) | C (2.3) |